Abivax (AAVXF) Liabilities and Shareholders Equity (2021 - 2026)

Abivax has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $640.6 million in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity rose 264.78% year-over-year to $640.6 million in Q1 2026; TTM through Mar 2026 was $2.2 billion, a 216.35% increase from a year earlier, with the FY2025 full-year figure at $680.2 million, up 210.16% from the prior year.
• Liabilities and Shareholders Equity was $640.6 million for Q1 2026 at Abivax, down from $680.2 million in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $762.3 million in Q3 2025, with the low at $77.1 million in Q4 2022.
• Average Liabilities and Shareholders Equity over 5 years is $372.1 million, with a median of $306.4 million recorded in 2024.
• The sharpest annual moves came in 2023 and 2025: Liabilities and Shareholders Equity soared 356.58% in 2023, then slumped 55.8% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $77.1 million in 2022, then jumped by 356.58% to $351.9 million in 2023, then plunged by 37.68% to $219.3 million in 2024, then jumped by 210.16% to $680.2 million in 2025, then retreated by 5.83% to $640.6 million in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $640.6 million (Q1 2026), $680.2 million (Q4 2025), and $762.3 million (Q3 2025), per Business Quant data.